Synthesis and antiinflammatory activity of 7-methanesulfonylamino-6-phenoxychromones. Antiarthritic effect of the 3-formylamino compound (T-614) in chronic inflammatory disease models

A group of derivatives of 7-methanesulfonylamino-6-phenoxychrome (1) at the pyrone and phenoxy rings was synthesized starting with 4-chloro-3-nitroanisole and evaluated against acute and chronic inflammations in oral administration in animals, Significant potency in the rat models of carrageenin-ind...

Full description

Saved in:
Bibliographic Details
Published inChemical & pharmaceutical bulletin Vol. 48; no. 1; pp. 131 - 139
Main Authors Inaba, T, Tanaka, K, Takeno, R, Nagaki, H, Yoshida, C, Takano, S
Format Journal Article
LanguageEnglish
Published TOKYO Pharmaceutical Soc Japan 01.01.2000
Maruzen
Subjects
Rat
Online AccessGet full text

Cover

Loading…
More Information
Summary:A group of derivatives of 7-methanesulfonylamino-6-phenoxychrome (1) at the pyrone and phenoxy rings was synthesized starting with 4-chloro-3-nitroanisole and evaluated against acute and chronic inflammations in oral administration in animals, Significant potency in the rat models of carrageenin-induced edema (CPE) and adjuvant-induced arthritis (AA) was realized with 2'-fluoro and 2',4'-difluoro derivatives (9a and 9d), and 3-formylamino derivative (19a) and its 2'-fluoro and 2',4'-diffuoro compounds (22a and 22d), displaying AA therapeutic effect of ED40 = 2.5-7.1 mg/kg/d for 7 d and AA prophylarrtic effect of 53-70% inhibition at the dosage of 3 mg/kg/d for 22 d. To identify a candidate for further pharmacological study, the five compounds, were subjected to evaluation of their gastro-ulcerogenic liability, leading to selection of the fluorine-free compound 19a which did not cause acute ulceration at 300 mg/kg in oral administration in rats, Compound 19a (ED40= 3.6 mg/kg in established AA) possessed good therapeutic efficacy against type II collagen-induced arthritis in DBA/1J mice with doses of 30 and 100 mg/kg, suggesting the development of 19a (designated T-614) as a prospective disease-modifying antirheumatic agent. In addition, a preparative-scale synthetic route to T-614 has been established.
ISSN:0009-2363
1347-5223
DOI:10.1248/cpb.48.131